Sinofn Health
Sinofn Health
In the rapidly evolving landscape of global nutraceuticals, SINOFN stands at the intersection of academic rigor and industrial efficiency. Established in 2012, our trajectory is defined by the integration of clinical research from the Chinese Academy of Sciences into commercially viable product lines.
Our R&D pipeline focuses on high-bioavailability formulations. By leveraging patent-protected technologies, we have successfully commercialized complex compounds such as cAMP (Cyclic Adenosine Monophosphate) and specialized PKU (Phenylketonuria) medical foods. Our goal is to shift from "supplement production" to "nutritional biotechnology," focusing on precision nutrition tailored to metabolic health and cellular longevity.
We have transitioned from traditional manufacturing to "Smart Manufacturing." Our facilities utilize IoT-enabled production lines, blockchain-based batch tracking, and full-process digital monitoring. This ensures that global partners receive products with verifiable provenance—critical for regulatory compliance in the EU, US, and beyond. Our 500M+ unit annual capacity ensures that we remain a resilient link in your global supply chain, minimizing lead times despite global logistics volatility.
Led by Dr. Tan Shengjie (Ph.D. Peking University), our medical team ensures that every formulation is backed by metabolic research, not just marketing trends.
Collaboration with the Chinese Academy of Sciences provides us with unparalleled access to bioactive compound development and clinical safety data.
Hans van Dijk, our Senior Scientist from the Netherlands, spearheads our EU regulatory framework alignment, ensuring seamless entry into the European market.
SINOFN serves a dual-purpose role: as a high-tech ODM (Original Design Manufacturer) and a supply chain partner. Whether you are a startup needing pilot-scale prototyping or a multinational brand requiring millions of units, our localized support model provides:
We adhere to strict international standards including ISO22000 and FSSC 22000. Our QC center utilizes advanced HPLC and GC-MS equipment for rigorous contaminant screening.
Yes. We offer pilot-scale production lines specifically designed to help emerging brands test product concepts before scaling to mass manufacturing.
It provides us with deep intellectual capital. Unlike standard manufacturers, we develop proprietary bioactive delivery systems that offer actual clinical efficacy, providing a competitive edge for your products.
